San Francisco, CA (January 10, 2026) — Xella Health, a women’s precision health and

telemedicine company focused on transforming how women understand their biology across

every life stage, today announced the close of more than $3.7 million in pre-seed financing.

The round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures,

and other funds. As well as strategic angel investors across healthcare, diagnostics, and

consumer technology.

Xella is defining a new category of women’s health—one that moves beyond symptom-based

care and fragmented testing to deliver integrated biological insight, clarity, and foresight. The

company combines advanced multi-omic diagnostics, longitudinal data, and personalized

clinician-led guidance to help women understand what’s happening in their bodies today—and

what’s likely ahead—across fertility, chronic conditions, hormonal health, early cancer

detection, and preventative care.

By pioneering the use of menstrual fluid alongside peripheral blood, Xella taps into powerful

biological signals that have historically been ignored—being able to tell women things like the

root cause of their menstrual irregularities and chronic pelvic pain, scores for egg quality, and

quantity, miscarriage risk, specific perimenopause stage, HRT personalization guidance, genetic

predispositions for reproductive cancers, and whole body aging insights. This is healthcare that

finally puts women first, giving women the power to decode what their bodies are telling them.

Despite women making up over half the population, the healthcare system has historically

treated female biology as secondary, under-researched, and episodic. Women are often

dismissed, misdiagnosed, or told their symptoms are “normal,” “just stress,” or something they

must learn to live with. Xella was founded to change that paradigm, co-founded by industry experts, Kelly Lacob, CEO (2x Stanford, Johns Hopkins, former Mammoth Biosciences), Adriana Dantas, COO (former Roche, BD), and Jesus Ching, PhD, CTO (former Mammoth Biosciences, Arc Bio).

“Our mission is to give women the answers and care they have always deserved,” said Kelly

Lacob, Co-Founder & CEO of Xella. “Xella is building the infrastructure to decode female

biology–getting to the root cause of conditions that uniquely, differently or disproportionately

affect women, many of which suffer from an unacceptably poor standard of care today. Every

woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure

that the complex data we analyze translates into meaningful, actionable health outcomes rather

than more noise. This funding allows us to accelerate product development and prepare for our

first launch.”

Investor demand has mirrored consumer interest. Ahead of its planned Spring 2026 launch,

Xella is on pace to attract more than 10,000 women to its waitlist, signaling strong appetite for

a more modern, data-driven approach to women’s health.

“Xella is rethinking women’s health from the ground up—starting with the insight women need to

make sense of their own biology over time,” said Ashtan Jordan, Principal at Precursor

Ventures. “The team is building with a rare combination of scientific depth, product intuition, and

empathy for the lived realities of women, which is exactly what’s required to create a trusted,

enduring platform in healthcare.”

“Xella represents the future of proactive, personalized care enabled at scale by AI—where early

detection can meaningfully change outcomes for women by going after one of the largest

unsolved problems in healthcare—early, personalized detection for women,” said Margaret

Coblentz, Co-Founder and General Partner at Capital F. “We’re thrilled to continue backing a

team with the scientific rigor, product vision, and cultural relevance to build a

category-defining company.”

The new capital will be used to finalize product development, expand strategic partnerships, and

support Xella’s upcoming market launch.

Xella has already made several key leadership hires, bringing on Taylor Hansen as Chief

Marketing and Commercial Officer (former Moet Hennessy-Louis Vuitton, VF Corporation), Olga

Sazonova, PhD as VP of Computational Biology (former GRAIL, 23andMe), and Andre De

Lucca as Lead Sr. Software Engineer (former Pr3vent, Alpargatas S.A.).

For more information or to join the waitlist, visit joinxella.com.

About Xella

Xella Health is redefining women’s healthcare. Our mission: to uncover the root causes behind women’s health concerns—from fertility and perimenopause to endometriosis, PCOS, early cancer detection and beyond. We’re pioneering first-of-its-kind, AI-powered multi-omic testing that makes precision medicine and concierge care accessible to all women. This is healthcare that finally puts women first—empowering women everywhere to Know Your CodeTM.